Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01262365 · ClinicalTrials.gov registry record · Phase 3
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 793
- Enrollment target
NCT01262365 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 793 participants.
The verdict
NCT01262365, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 793 participants
- Enrollment target
Study Summary
The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)
Interventions
- DRUG Placebo
- DRUG Epratuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 793 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01262365
The ClinicalTrials.gov registry entry for NCT01262365 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 793 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01262365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01262365 about?
NCT01262365 is a clinical study titled "Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus". The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)
What is the current status of trial NCT01262365?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 793 participants. The study started on 2010-12. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01262365?
The interventions under investigation include: Placebo (DRUG), Epratuzumab (DRUG).
Who is sponsoring clinical trial NCT01262365?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.